Dose relationship between GnRH antagonists and pituitary suppression

J. Rivier, G. C. Jiang, S. L. Lahrichi, J. Porter, S. C. Koerber, J. Rizo, A. Corrigan, L. Gierasch, A. Hagler, W. Vale, C. Rivier

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

While the clinical significance of gonadotrophin-releasing hormone (GnRH) agonists is well recognized, the potential use of GnRH antagonists in humans awaits the availability of potent analogues with no untoward side-effects. We have designed, synthesized and tested several hundred linear and cyclic analogues (agonists and antagonists) of GnRH in different rat models; some have high histamine releasing activity and others have poor solubility in aqueous buffers with a pH > 6.0. Furthermore, we have identified analogues exhibiting short (< 12 h), intermediate (12-72 h) and long (> 72 h) duration of action in the rat (50 μg s.c. dose/rat). We have concluded that the basis for such resistance to degradation and elimination must be specific. In order to gain further information on the optimal nature and sterical requirements of side-chains, preliminary experiments were carried out using betidamino acids. Finally, mono- and dicyclic analogues of GnRH with potencies comparable with that of the most potent linear analogues were also obtained. Our approach to the development of such analogues included the use of nuclear magnetic resonance and computational techniques as well as that of state-of-the-art synthetic approaches. We intend to use the information derived from these structure/activity relationship studies to design conformationally-similar peptido-mimetics.

Original languageEnglish (US)
Pages (from-to)133-147
Number of pages15
JournalHuman Reproduction
Volume11
Issue numberSUPPL. 3
StatePublished - Nov 1996

Fingerprint

Hormone Antagonists
Gonadotropin-Releasing Hormone
Structure-Activity Relationship
Solubility
Histamine
Buffers
Magnetic Resonance Spectroscopy
Acids

Keywords

  • Acyline
  • Azaline B
  • Betidamino acids
  • Drug design
  • GnRH antagonists

ASJC Scopus subject areas

  • Physiology
  • Developmental Biology
  • Obstetrics and Gynecology
  • Reproductive Medicine

Cite this

Rivier, J., Jiang, G. C., Lahrichi, S. L., Porter, J., Koerber, S. C., Rizo, J., ... Rivier, C. (1996). Dose relationship between GnRH antagonists and pituitary suppression. Human Reproduction, 11(SUPPL. 3), 133-147.

Dose relationship between GnRH antagonists and pituitary suppression. / Rivier, J.; Jiang, G. C.; Lahrichi, S. L.; Porter, J.; Koerber, S. C.; Rizo, J.; Corrigan, A.; Gierasch, L.; Hagler, A.; Vale, W.; Rivier, C.

In: Human Reproduction, Vol. 11, No. SUPPL. 3, 11.1996, p. 133-147.

Research output: Contribution to journalArticle

Rivier, J, Jiang, GC, Lahrichi, SL, Porter, J, Koerber, SC, Rizo, J, Corrigan, A, Gierasch, L, Hagler, A, Vale, W & Rivier, C 1996, 'Dose relationship between GnRH antagonists and pituitary suppression', Human Reproduction, vol. 11, no. SUPPL. 3, pp. 133-147.
Rivier J, Jiang GC, Lahrichi SL, Porter J, Koerber SC, Rizo J et al. Dose relationship between GnRH antagonists and pituitary suppression. Human Reproduction. 1996 Nov;11(SUPPL. 3):133-147.
Rivier, J. ; Jiang, G. C. ; Lahrichi, S. L. ; Porter, J. ; Koerber, S. C. ; Rizo, J. ; Corrigan, A. ; Gierasch, L. ; Hagler, A. ; Vale, W. ; Rivier, C. / Dose relationship between GnRH antagonists and pituitary suppression. In: Human Reproduction. 1996 ; Vol. 11, No. SUPPL. 3. pp. 133-147.
@article{8c6acf96bed84142b0e91c5511732642,
title = "Dose relationship between GnRH antagonists and pituitary suppression",
abstract = "While the clinical significance of gonadotrophin-releasing hormone (GnRH) agonists is well recognized, the potential use of GnRH antagonists in humans awaits the availability of potent analogues with no untoward side-effects. We have designed, synthesized and tested several hundred linear and cyclic analogues (agonists and antagonists) of GnRH in different rat models; some have high histamine releasing activity and others have poor solubility in aqueous buffers with a pH > 6.0. Furthermore, we have identified analogues exhibiting short (< 12 h), intermediate (12-72 h) and long (> 72 h) duration of action in the rat (50 μg s.c. dose/rat). We have concluded that the basis for such resistance to degradation and elimination must be specific. In order to gain further information on the optimal nature and sterical requirements of side-chains, preliminary experiments were carried out using betidamino acids. Finally, mono- and dicyclic analogues of GnRH with potencies comparable with that of the most potent linear analogues were also obtained. Our approach to the development of such analogues included the use of nuclear magnetic resonance and computational techniques as well as that of state-of-the-art synthetic approaches. We intend to use the information derived from these structure/activity relationship studies to design conformationally-similar peptido-mimetics.",
keywords = "Acyline, Azaline B, Betidamino acids, Drug design, GnRH antagonists",
author = "J. Rivier and Jiang, {G. C.} and Lahrichi, {S. L.} and J. Porter and Koerber, {S. C.} and J. Rizo and A. Corrigan and L. Gierasch and A. Hagler and W. Vale and C. Rivier",
year = "1996",
month = "11",
language = "English (US)",
volume = "11",
pages = "133--147",
journal = "Human Reproduction",
issn = "0268-1161",
publisher = "Oxford University Press",
number = "SUPPL. 3",

}

TY - JOUR

T1 - Dose relationship between GnRH antagonists and pituitary suppression

AU - Rivier, J.

AU - Jiang, G. C.

AU - Lahrichi, S. L.

AU - Porter, J.

AU - Koerber, S. C.

AU - Rizo, J.

AU - Corrigan, A.

AU - Gierasch, L.

AU - Hagler, A.

AU - Vale, W.

AU - Rivier, C.

PY - 1996/11

Y1 - 1996/11

N2 - While the clinical significance of gonadotrophin-releasing hormone (GnRH) agonists is well recognized, the potential use of GnRH antagonists in humans awaits the availability of potent analogues with no untoward side-effects. We have designed, synthesized and tested several hundred linear and cyclic analogues (agonists and antagonists) of GnRH in different rat models; some have high histamine releasing activity and others have poor solubility in aqueous buffers with a pH > 6.0. Furthermore, we have identified analogues exhibiting short (< 12 h), intermediate (12-72 h) and long (> 72 h) duration of action in the rat (50 μg s.c. dose/rat). We have concluded that the basis for such resistance to degradation and elimination must be specific. In order to gain further information on the optimal nature and sterical requirements of side-chains, preliminary experiments were carried out using betidamino acids. Finally, mono- and dicyclic analogues of GnRH with potencies comparable with that of the most potent linear analogues were also obtained. Our approach to the development of such analogues included the use of nuclear magnetic resonance and computational techniques as well as that of state-of-the-art synthetic approaches. We intend to use the information derived from these structure/activity relationship studies to design conformationally-similar peptido-mimetics.

AB - While the clinical significance of gonadotrophin-releasing hormone (GnRH) agonists is well recognized, the potential use of GnRH antagonists in humans awaits the availability of potent analogues with no untoward side-effects. We have designed, synthesized and tested several hundred linear and cyclic analogues (agonists and antagonists) of GnRH in different rat models; some have high histamine releasing activity and others have poor solubility in aqueous buffers with a pH > 6.0. Furthermore, we have identified analogues exhibiting short (< 12 h), intermediate (12-72 h) and long (> 72 h) duration of action in the rat (50 μg s.c. dose/rat). We have concluded that the basis for such resistance to degradation and elimination must be specific. In order to gain further information on the optimal nature and sterical requirements of side-chains, preliminary experiments were carried out using betidamino acids. Finally, mono- and dicyclic analogues of GnRH with potencies comparable with that of the most potent linear analogues were also obtained. Our approach to the development of such analogues included the use of nuclear magnetic resonance and computational techniques as well as that of state-of-the-art synthetic approaches. We intend to use the information derived from these structure/activity relationship studies to design conformationally-similar peptido-mimetics.

KW - Acyline

KW - Azaline B

KW - Betidamino acids

KW - Drug design

KW - GnRH antagonists

UR - http://www.scopus.com/inward/record.url?scp=13144281714&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=13144281714&partnerID=8YFLogxK

M3 - Article

VL - 11

SP - 133

EP - 147

JO - Human Reproduction

JF - Human Reproduction

SN - 0268-1161

IS - SUPPL. 3

ER -